MYZOMIB 2MG

Myzomib 2mg Injection is a chemotherapy drug classified as a proteasome inhibitor. Its active component is Bortezomib. This medication is prescribed for treating multiple myeloma and mantle cell lymphoma. Multiple myeloma is characterized by the cancerous growth of plasma cells primarily found in the bone marrow. Mantle cell lymphoma, on the other hand, is a rarer form of cancer that impacts the lymph nodes. Myzomib is often used in conjunction with other chemotherapy agents such as pegylated liposomal doxorubicin, rituximab, cyclophosphamide, doxorubicin, dexamethasone, prednisolone, or thalidomide for patients who have not yet begun treatment and are not candidates for blood stem cell transplantation.

Common side effects associated with Myzomib 2mg Injection include pneumonia, decreased appetite, skin sensitivity, tingling and burning sensations, nausea, vomiting, diarrhea, mouth sores, constipation, muscle and bone pain, hair loss, fever, infections, itching, redness, dehydration, and gastrointestinal issues. It is important to inform your physician if these side effects are bothersome or persist.

Notify your doctor if you have an allergy to Myzomib 2mg Injection or any of its components. This medication should not be used if you have severe lung or heart conditions. Prior to starting treatment, inform your physician if you have neuropathy (nerve dysfunction), heart disorders, severe lung issues, pulmonary disorders, posterior reversible encephalopathy syndrome, gastrointestinal disorders, thrombocytopenia (low platelet count), neutropenia (low white blood cell count), tumor lysis syndrome (a metabolic complication that can arise during cancer treatment), or liver disorders. Additionally, inform your doctor if you have diabetes, as this injection may influence your blood glucose levels.